Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558686 | 0.93 | DPP4 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6559250 | 0.85 | KCNE1 (0.44) | KCNE1KCNQ1KCNH2 | |
| SCHEMBL6558683 | 0.85 | KCNE1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6559549 | 0.84 | KCNE1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7826231 | 0.82 | KCNE1 (0.36) | KCNE1KCNQ1KCNH2 | |
| SCHEMBL6558719 | 0.82 | KCNE1 (0.46) | KCNE1KCNQ1KCNH2 | |
| SCHEMBL6560826 | 0.82 | HTR2B (0.35) | KCNE1KCNQ1KCNH2 | |
| SCHEMBL6559601 | 0.81 | MAPT (0.31) | — | |
| SCHEMBL7826743 | 0.81 | KCNE1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7830067 | 0.80 | KCNE1 (0.37) | KCNE1KCNQ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-09 | — | — | US | claimed |
| US-6335363-B1 | ADMINISTERING 4-(SULFONYLAMINO-)-CHROMANE DERIVATIVE AS INSECTICIDE, NEMATOCIDE, FUNGICIDE OR PESTICIDE FOR CROP PROTECTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | claimed |
| EP-1140042-B1 | UTILIZATION OF INHIBITORS OF THE KQT1 CHANNEL IN ORDER TO PRODUCE A MEDICAMENT FOR TREATING DISEASES WHICH ARE CAUSED BY PARASITIC HELMINTHS AND ECTOPARASITES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055537-A1 | Use of inhibitors of the KQT1 channel and methods of controlling and treating diseases caused by helminths and ectoparasites | KCNQ1, KCNQ2, KCNQ3 | PSEN1 957/4885PSEN2 2067/4885APH1B 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.